Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

December 10, 2018

Study Completion Date

November 19, 2020

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

zilucoplan (RA101495)

Daily subcutaneous (SC) injection

DRUG

Placebo

Daily subcutaneous (SC) injection

Trial Locations (30)

10021

Hospital for Special Surgery, New York

10029

Mount Sinai Hospital, New York

14260

University of Buffalo, Buffalo

15212

Allegheny Neurological Associates, Pittsburgh

20052

George Washington University, Washington D.C.

21201

University of Maryland, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

32209

University of Florida, Jacksonville

33620

University of South Florida, Tampa

36604

Diagnostic and Medical Clinic - Mobile, Mobile

38018

Wesley Neurology Clinic, Cordova

43210

Ohio State University, Columbus

48202

Wayne State University, Detroit

48864

Michigan State University, East Lansing

53215

Center for Neurological Disorders, Milwaukee

60612

Rush University Medical Center, Chicago

66160

University of Kansas Medical Center, Kansas City

75390

University of Texas Southwestern, Dallas

84132

University of Utah, Salt Lake City

90095

UCLA Medical Center, Los Angeles

92011

The Research Center of Southern California, Carlsbad

92868

University of California Irvine Health ALS and Neuromuscular Center, Orange

06520

Yale University, New Haven

02114

Massachusetts General Hospital, Boston

01805

Lahey Hospital and Medical Center, Burlington

05405

University of Vermont, Burlington

T6G 2B7

University of Alberta Hospital, Edmonton

N6A 5A5

London Health Sciences Centre University Hospital, London

M5G 2C4

Toronto General Hospital, Toronto

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ra Pharmaceuticals

INDUSTRY